天津医药

• 论著 • 上一篇    下一篇

Graves 病患者Th1/Th2趋化因子失衡的初步探讨

崔巧丽1,樊继援2,邱明才2   

  1. 1. 河南科技大学第一附属医院
    2. 天津医科大学总医院
  • 收稿日期:2010-07-26 修回日期:2010-11-24 出版日期:2011-06-15 发布日期:2011-06-15
  • 通讯作者: 樊继援

The preliminary study on the imbalance ofTh1/Th2 chemokines in patient with Graves disease

  • Received:2010-07-26 Revised:2010-11-24 Published:2011-06-15 Online:2011-06-15

PDF (PC)

2118

摘要： 目的:探讨Graves 病（GD）患者血清Thl／Th2趋化因子CXCL10、CCL22水平的变化及其临床意义；方法：76例患者按照诊治阶段分为治疗前组、治疗缓解组和治疗平稳组，ELISA法检测血清趋化因子CXCL10、CCL22的水平，并结合患者临床指标进行分析。结果：GD患者血清CXCL10、CCL22水平在治疗前显著升高，比值在治疗前亦明显高于治疗后各组（均p<0.001）。治疗后患者血清CXCL10、CCL22水平明显下降，治疗缓解组甚至低于正常对照组（均p<0.01）。GD患者治疗前血清CXCL10、CCL22均与患者血清FT4水平呈正相关（r CXCL10=0.538，r CCL22=0.389,p<0.05）。结论：趋化因子CXCL10、CCL22参与GD的免疫调控，并且与疾病进程相关，可为免疫学监测提供新的思路。

关键词: Graves 病, 趋化因子, 自身免疫, CXCL10, CCL22

Abstract: Objective: To explore the changes of Th1/Th2 chemokines CXCL10、CCL22 and its clinical significance in the patient with Graves disease. Method: 76 outpatient with Graves disease in different stage of treatment were selected,including untreated group、remission、stable group and control group. We collected the datas including thyroid function、thyroid antibodys，as well as the level of serum CXCL10 and CCL22 detected by ELISA. Results: Serum CXCL10、CCL22 level were significantly increased in untreaded group（p<0.001）,after treatment CXCL10、CCL22 levels the ratio(CXCL10/CCL22) were significantly decreased(p<0.01),and in the remission group the levels were lower than normal(p<0.01). The levels of CXCL10、CCL22 were positively correlated with FT4( r=0.538，r=0.389, respectively). Conclusion: Th1/Th2 chemokines CXCL10、CCL22 were involved in the immune regulation of Graves

Key words: Graves disease, chemokine, autoimmune, CXCL10, CCL22